According to the research report titled ‘Global Transcatheter Tricuspid Valve Intervention (TTVI) Market - Analysis By Intervention Type (TVr, TVR), Disease Type (TR, TS), End User, By Region, By Country (2021 Edition): Market Insights, Pipeline, COVID-19 Implications, Competition and Forecast (2021-2030)’, available with MarketStudyReport, global transcatheter tricuspid valve intervention (TTVI) market is expected to reach a valuation of USD 10.17 billion by the end of forecast period 2021-2030.
 

Rapid increase in aging population, breakthroughs and technological progressions in tricuspid valve intervention devices, and upcoming clinical approvals are propelling the growth of global transcatheter tricuspid valve intervention (TTVI) market.
 

Request sample copy of this report: https://www.marketstudyreport.com/request-a-sample/4331005/
 

Moreover, growing preference for such devices for treatment, as a result of the rising tendency to opt for minimally invasive surgeries over traditional open-heart surgeries is speeding up the industry development. 
 

During the COVID-19 pandemic, the health crisis wreaked havoc on a variety of industries, including the cardiovascular care sector. Due to the lockdowns and stay-at-home orders, there was a significant delay in regulatory clearances and approvals of repair & replacement activities, as well as disruptions in clinical trials and pipeline milestones, which hampered the industry's overall advancement.
 

From a regional standpoint, Europe transcatheter tricuspid valve intervention (TTVI) market is poised to expand substantially over 2021-2025, owing to early sanctions of these devices, rising incidence of valve disorders in the aging population, elevated per-capita income and improved healthcare spending in the region.
 

Whereas Asia Pacific market is predicted to record noteworthy growth during the period 2026-2030. This can be attributed to factors such as vast unaddressed requirements of patients suffering from tricuspid valve disorders, substantial improvement in healthcare tourism, developments in healthcare infrastructure, and increased spending in medical care by both the private and public sectors.
 

The competitive landscape of global transcatheter tricuspid valve intervention (TTVI) industry is defined by companies such as Shanghai Huihe Healthcare Technology Co. Ltd., Abbott Laboratories, Venus MedTech, Inc., NaviGate Cardiac Structures, Inc., LivaNova plc, Jenscare Scientific Co., CryoLife, Inc., Medtronic Plc, Edwards Lifesciences Corp., and Tech Cardio Ireland Ltd. among others.